This month, HRSA published a pair of manuscripts demonstrating the cost-effectiveness of the Ryan White HIV/AIDS Program (RWHAP) in the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
These two papers present findings from the first formal evaluation of the RWHAP’s cost-effectiveness at a national level. The first paper presents a new and innovative mathematical model that can be used as a tool for estimating the cost-effectiveness of the RWHAP under a variety of policy scenarios and assumptions. The second paper compares estimated health care costs and outcomes over a 50-year period in the presence of the RWHAP relative to those expected if the comprehensive and integrated system of medical and support services funded by the RWHAP were not available.
Read the first paper.
Read the second paper.